212 related articles for article (PubMed ID: 25900274)
1. (131)I treatment for thyroid cancer and the risk of developing salivary and lacrimal gland dysfunction and a second primary malignancy: a nationwide population-based cohort study.
Ko KY; Kao CH; Lin CL; Huang WS; Yen RF
Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1172-8. PubMed ID: 25900274
[TBL] [Abstract][Full Text] [Related]
2. Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy.
Solans R; Bosch JA; Galofré P; Porta F; Roselló J; Selva-O'Callagan A; Vilardell M
J Nucl Med; 2001 May; 42(5):738-43. PubMed ID: 11337569
[TBL] [Abstract][Full Text] [Related]
3. Risk of Breast Cancer in Patients with Thyroid Cancer Receiving or Not Receiving 131I Treatment: A Nationwide Population-Based Cohort Study.
Lin CY; Lin CL; Huang WS; Kao CH
J Nucl Med; 2016 May; 57(5):685-90. PubMed ID: 26719377
[TBL] [Abstract][Full Text] [Related]
4. Salivary and lacrimal gland dysfunction after remnant ablation with radioactive iodine in patients with differentiated thyroid carcinoma prepared with recombinant human thyrotropin.
Rosario PW; Calsolari MR
Thyroid; 2013 May; 23(5):617-9. PubMed ID: 23136908
[TBL] [Abstract][Full Text] [Related]
5. Use of Radioactive Iodine for Thyroid Cancer and Risk of Second Primary Malignancy: A Nationwide Population-Based Study.
Teng CJ; Hu YW; Chen SC; Yeh CM; Chiang HL; Chen TJ; Liu CJ
J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26538627
[TBL] [Abstract][Full Text] [Related]
6. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer?
Nakada K; Ishibashi T; Takei T; Hirata K; Shinohara K; Katoh S; Zhao S; Tamaki N; Noguchi Y; Noguchi S
J Nucl Med; 2005 Feb; 46(2):261-6. PubMed ID: 15695785
[TBL] [Abstract][Full Text] [Related]
7. Second Primary Cancer in Patients with Differentiated Thyroid Cancer: Does Radioiodine Play a Role?
Silva-Vieira M; Carrilho Vaz S; Esteves S; Ferreira TC; Limbert E; Salgado L; Leite V
Thyroid; 2017 Aug; 27(8):1068-1076. PubMed ID: 28614983
[TBL] [Abstract][Full Text] [Related]
8. Intermediate and long-term adverse effects of radioiodine therapy for differentiated thyroid carcinoma--a systematic review.
Clement SC; Peeters RP; Ronckers CM; Links TP; van den Heuvel-Eibrink MM; Nieveen van Dijkum EJ; van Rijn RR; van der Pal HJ; Neggers SJ; Kremer LC; van Eck-Smit BL; van Santen HM
Cancer Treat Rev; 2015 Dec; 41(10):925-34. PubMed ID: 26421813
[TBL] [Abstract][Full Text] [Related]
9. Quantitative evaluation of salivary gland dysfunction after radioiodine therapy using salivary gland scintigraphy.
Raza H; Khan AU; Hameed A; Khan A
Nucl Med Commun; 2006 Jun; 27(6):495-9. PubMed ID: 16710103
[TBL] [Abstract][Full Text] [Related]
10. 131I treatment for thyroid cancer and risk of developing primary hyperparathyroidism: a cohort study.
Lin CM; Doyle P; Tsan YT; Lee CH; Wang JD; Chen PC;
Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):253-9. PubMed ID: 23982456
[TBL] [Abstract][Full Text] [Related]
11. The effect of high-dose radioiodine treatment on lacrimal gland function in patients with differentiated thyroid carcinoma.
Fard-Esfahani A; Mirshekarpour H; Fallahi B; Eftekhari M; Saghari M; Beiki D; Ansari-Gilani K; Takavar A
Clin Nucl Med; 2007 Sep; 32(9):696-9. PubMed ID: 17710021
[TBL] [Abstract][Full Text] [Related]
12. Estimation of Second Primary Cancer Risk After Treatment with Radioactive Iodine for Differentiated Thyroid Carcinoma.
Corrêa NL; de Sá LV; de Mello RC
Thyroid; 2017 Feb; 27(2):261-270. PubMed ID: 27762670
[TBL] [Abstract][Full Text] [Related]
13. Effects of Radioiodine Treatment on Salivary Gland Function in Patients with Differentiated Thyroid Carcinoma: A Prospective Study.
Klein Hesselink EN; Brouwers AH; de Jong JR; van der Horst-Schrivers AN; Coppes RP; Lefrandt JD; Jager PL; Vissink A; Links TP
J Nucl Med; 2016 Nov; 57(11):1685-1691. PubMed ID: 27339871
[TBL] [Abstract][Full Text] [Related]
14. Risk of second primary malignancy in differentiated thyroid carcinoma treated with radioactive iodine therapy.
Lang BH; Wong IO; Wong KP; Cowling BJ; Wan KY
Surgery; 2012 Jun; 151(6):844-50. PubMed ID: 22341041
[TBL] [Abstract][Full Text] [Related]
15. Salivary gland malignancy and radioiodine therapy for thyroid cancer.
Klubo-Gwiezdzinska J; Van Nostrand D; Burman KD; Vasko V; Chia S; Deng T; Kulkarni K; Wartofsky L
Thyroid; 2010 Jun; 20(6):647-51. PubMed ID: 20470209
[TBL] [Abstract][Full Text] [Related]
16. Increased risk of second primary malignancy in pediatric and young adult patients treated with radioactive iodine for differentiated thyroid cancer.
Marti JL; Jain KS; Morris LG
Thyroid; 2015 Jun; 25(6):681-7. PubMed ID: 25851829
[TBL] [Abstract][Full Text] [Related]
17. Assessment of salivary gland dysfunction after radioiodine therapy for thyroid carcinoma using non-contrast-enhanced CT: the significance of changes in volume and attenuation of the glands.
Nabaa B; Takahashi K; Sasaki T; Okizaki A; Aburano T
AJNR Am J Neuroradiol; 2012 Nov; 33(10):1964-70. PubMed ID: 22555571
[TBL] [Abstract][Full Text] [Related]
18. Re: does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer?
Lam MG; van Isselt JW
J Nucl Med; 2005 Dec; 46(12):2118; author reply 2118-9. PubMed ID: 16330579
[No Abstract] [Full Text] [Related]
19. Dysfunction of the Salivary and Lacrimal Glands After Radioiodine Therapy for Thyroid Cancer: Results of the START Study After 6-Months of Follow-Up.
Baudin C; Bressand A; Buffet C; Menegaux F; Soret M; Lê AT; Cardon T; Broggio D; Bassinet C; Huet C; Armengol G; Richardson DB; Leenhardt L; Bernier MO; Lussey-Lepoutre C
Thyroid; 2023 Sep; 33(9):1100-1109. PubMed ID: 37300484
[No Abstract] [Full Text] [Related]
20. Incidence of Nonthyroidal Primary Malignancy and the Association with (131)I Treatment in Patients with Differentiated Thyroid Cancer.
Hirsch D; Shohat T; Gorshtein A; Robenshtok E; Shimon I; Benbassat C
Thyroid; 2016 Aug; 26(8):1110-6. PubMed ID: 27302111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]